For antibody drug conjugates to reach their full potential, developers should focus on addressing current challenges such as safety and efficacy.
Andreas Dreps
Advertisement
Senior VP and Global Head Drug Development Unit, ICON plc
Articles by Andreas Dreps
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Execution Failures and Upstream Origins, European Data Governance Reshaping CROs, and Phase-Dependent Trial Competition
2
Real-World Evidence in Transition: CRO Adaptation to the European Health Data Space Framework
3
ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism
4
The AI Churn Trap in Life Sciences and How to Break It
5